Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Steeg Website

Patricia S. Steeg, Ph.D.

Selected Publications

1)  McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.
A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.
Breast Cancer Res. 16: R25, 2014.
2)  Morikawa A, Peereboom DM, Thorsheim HR, Samala R, Balyan R, Murphy CG, Lockman PR, Simmons A, Weil RJ, Tabar V, Steeg PS, Smith QR, Seidman AD.
Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study.
Neuro-oncology. [Epub ahead of print], 2014.
3)  Woditschka S, Evans L, Duchnowska R, Reed LT, Palmieri D, Qian Y, Badve S, Sledge G, Gril B, Aladjem MI, Fu H, Flores NM, Gökmen-Polar Y, Biernat W, Szutowicz-Zielinska E, Mandat T, Trojanowski T, Och W, Czartoryska-Arlukowicz B, Jassem J, Mitchell JB, Steeg PS.
DNA double-strand break repair genes and oxidative damage in brain metastasis of breast cancer.
J. Natl. Cancer Inst. 106, 2014.
4)  Marino N, Collins JW, Shen C, Caplen NJ, Merchant AS, Gökmen-Polar Y, Goswami CP, Hoshino T, Qian Y, Sledge GW, Steeg PS.
Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.
Clin. Exp. Metastasis. [Epub ahead of print], 2014.
5)  Palmieri D, Duchnowska R, Woditschka S, Hua E, Qian Y, Biernat W, Sosilska-Mielcarek K, Gril B, Stark AM, Hewitt SM, Liewehr DJ, Steinberg SM, Jassem J, Steeg PS.
Profound Prevention of Experimental Brain Metastases of Breast Cancer by Temozolomide in an MGMT-Dependent Manner.
Clin. Cancer Res. [Epub ahead of print], 2014.
6)  Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton P, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Janeway KA, Weigel BJ, Randall RL, Meltzer PS, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Uren A, Patel S, Trent JM, Savage SA, Mirabello L, Reinke D, Barkauskas DA, Smith MA, Bernstein ML, Kirsch DG, Krailo MD.
Towards a Drug Development Path that Targets Metastatic Progression in Osteosarcoma.
Clin. Cancer Res. [Epub ahead of print], 2014.
7)  Peer CJ, Rao M, Spencer SD, Shahbazi S, Steeg PS, Schrump DS, Figg WD.
A rapid ultra HPLC-MS/MS method for the quantitation and pharmacokinetic analysis of 3-deazaneplanocin A in mice.
J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 927: 142-6, 2013.
8)  Marino N, Woditschka S, Reed LT, Nakayama J, Mayer M, Wetzel M, Steeg PS.
Breast cancer metastasis: issues for the personalization of its prevention and treatment.
Am. J. Pathol. 183: 1084-95, 2013.
9)  Lin NU, Amiri-Kordestani L, Palmieri D, Liewehr DJ, Steeg PS.
CNS metastases in breast cancer: old challenge, new frontiers.
Clin. Cancer Res. 19: 6404-18, 2013.
10)  Spano D, Marshall JC, Marino N, De Martino D, Romano A, Scoppettuolo MN, Bello AM, Di Dato V, Navas L, De Vita G, Medaglia C, Steeg PS, Zollo M.
Dipyridamole prevents triple-negative breast-cancer progression.
Clin. Exp. Metastasis. 30: 47-68, 2013.
11)  Saldana SM, Lee HH, Lowery FJ, Khotskaya YB, Xia W, Zhang C, Chang SS, Chou CK, Steeg PS, Yu D, Hung MC.
Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis.
PLoS ONE. 8: e73406, 2013.
12)  Wei JS, Johansson P, Chen L, Song YK, Tolman C, Li S, Hurd L, Patidar R, Wen X, Badgett TC, Cheuk AT, Marshall JC, Steeg PS, Vaqué Díez JP, Yu Y, Gutkind JS, Khan J.
Massively parallel sequencing reveals an accumulation of de novo mutations and an activating mutation of LPAR1 in a patient with metastatic neuroblastoma.
PLoS ONE. 8: e77731, 2013.
13)  Marino N, Marshall JC, Collins JW, Zhou M, Qian Y, Veenstra T, Steeg PS.
Nm23-h1 binds to gelsolin and inactivates its actin-severing capacity to promote tumor cell motility and metastasis.
Cancer Res. 73: 5949-62, 2013.
14)  Mittapalli RK, Liu X, Adkins CE, Nounou MI, Bohn KA, Terrell TB, Qhattal HS, Geldenhuys WJ, Palmieri D, Steeg PS, Smith QR, Lockman PR.
Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model.
Mol. Cancer Ther. 12: 2389-99, 2013.
15)  Gril B, Palmieri D, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Andreu Z, Masana D, Fernández P, Steeg PS, Vidal-Vanaclocha F.
Pazopanib Inhibits the Activation of PDGFRß-Expressing Astrocytes in the Brain Metastatic Microenvironment of Breast Cancer Cells.
Am. J. Pathol. 182: 2368-79, 2013.
16)  Brabletz T, Lyden D, Steeg PS, Werb Z.
Roadblocks to translational advances on metastasis research.
Nat. Med. 19: 1104-9, 2013.
17)  Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, Aldape KD, Steeg PS, Yu D.
SRC family kinases as novel therapeutic targets to treat breast cancer brain metastases.
Cancer Res. 73: 5764-74, 2013.
18)  Cantley LC, Dalton WS, DuBois RN, Finn OJ, Futreal PA, Golub TR, Hait WN, Lozano G, Maris JM, Nelson WG, Sawyers CL, Schreiber SL, Spitz MR, Steeg PS.
AACR Cancer Progress Report 2012.
Clin. Cancer Res. 18: S1-100, 2012.
19)  Marshall JC, Collins JW, Nakayama J, Horak CE, Liewehr DJ, Steinberg SM, Albaugh M, Vidal-Vanaclocha F, Palmieri D, Barbier M, Murone M, Steeg PS.
Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer.
J. Natl. Cancer Inst. 104: 1306-19, 2012.
20)  Marino N, Nakayama J, Collins JW, Steeg PS.
Insights into the biology and prevention of tumor metastasis provided by the Nm23 metastasis suppressor gene.
Cancer Metastasis Rev. 31: 593-603, 2012.
21)  Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, Gril B, Hua E, Palmieri D, Polli JW, Castellino S, Rubin SD, Lockman PR, Steeg PS, Smith QR.
Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer.
Pharm. Res. 29: 770-81, 2012.
22)  Fitzgerald DP, Subramanian P, Deshpande M, Graves C, Gordon I, Qian Y, Snitkovsky Y, Liewehr DJ, Steinberg SM, Paltán-Ortiz JD, Herman MM, Camphausen K, Palmieri D, Becerra SP, Steeg PS.
Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage.
Cancer Res. 72: 144-53, 2012.
23)  Steeg PS.
Perspective: The right trials.
Nature. 485: S58-9, 2012.
24)  Liu H, Kato Y, Erzinger SA, Kiriakova GM, Qian Y, Palmieri D, Steeg PS, Price JE.
The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model.
BMC Cancer. 12: 583, 2012.
25)  Fitzgerald DP, Emerson DL, Qian Y, Anwar T, Liewehr DJ, Steinberg SM, Silberman S, Palmieri D, Steeg PS.
TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells.
Mol. Cancer Ther. 11: 1959-67, 2012.
26)  Steeg PS, Zollo M, Wieland T.
A critical evaluation of biochemical activities reported for the nucleoside diphosphate kinase/Nm23/Awd family proteins: opportunities and missteps in understanding their biological functions.
Naunyn Schmiedeberg's Arch. Pharmacol. 384: 331-9, 2011.
27)  Steeg PS, Camphausen KA, Smith QR.
Brain metastases as preventive and therapeutic targets.
Nat. Rev. Cancer. 11: 352-63, 2011.
28)  Chiu W, Lee H, Huang F, Aldape KD, Yao J, Steeg PS, Chou C, Lu Z, Xie K, Huang S.
Caveolin-1 Upregulation Mediates Suppression of Primary Breast Tumor Growth and Brain Metastases by Stat3 Inhibition.
Cancer Res. 71: 4932-4943, 2011.
29)  Percy DB, Ribot EJ, Chen Y, McFadden C, Simedrea C, Steeg PS, Chambers AF, Foster PJ.
In Vivo Characterization of Changing Blood-Tumor Barrier Permeability in a Mouse Model of Breast Cancer Metastasis: A Complementary Magnetic Resonance Imaging Approach.
Invest. Radiol. 46: 718-25, 2011.
30)  Ribot EJ, Martinez-Santiesteban FM, Simedrea C, Steeg PS, Chambers AF, Rutt BK, Foster PJ.
In vivo single scan detection of both iron-labeled cells and breast cancer metastases in the mouse brain using balanced steady-state free precession imaging at 1.5 T.
J Magn Reson Imaging. 34: 231-8, 2011.
31)  Qian Y, Hua E, Bisht K, Woditschka S, Skordos KW, Liewehr DJ, Steinberg SM, Brogi E, Akram MM, Killian JK, Edelman DC, Pineda M, Scurci S, Degenhardt YY, Laquerre S, Lampkin TA, Meltzer PS, Camphausen K, Steeg PS, Palmieri D.
Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain.
Clin. Exp. Metastasis. 28: 899-908, 2011.
32)  McGowan PM, Simedrea C, Ribot EJ, Foster PJ, Palmieri D, Steeg PS, Allan AL, Chambers AF.
Notch1 Inhibition Alters the CD44hi/CD24lo Population and Reduces the Formation of Brain Metastases from Breast Cancer.
Mol. Cancer Res. 9: 834-44, 2011.
33)  Gril B, Palmieri D, Qian Y, Smart D, Ileva L, Liewehr DJ, Steinberg SM, Steeg PS.
Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis.
Clin. Cancer Res. 17: 142-53, 2011.
34)  Marino N, Marshall J, Steeg PS.
Protein-protein interactions: a mechanism regulating the anti-metastatic properties of Nm23-H1.
Naunyn-Schmiedeberg's Arch. Pharmacol. 384: 351-62, 2011.
35)  Gril B, Palmieri D, Qian Y, Anwar T, Ileva L, Bernardo M, Choyke P, Liewehr DJ, Steinberg SM, Steeg PS.
The B-Raf status of tumor cells may be a significant determinant of both antitumor and anti-angiogenic effects of pazopanib in xenograft tumor models.
PLoS ONE. 6: e25625, 2011.
36)  Sleeman J, Steeg PS.
Cancer metastasis as a therapeutic target.
Eur. J. Cancer. 46: 1177-80, 2010.
37)  Chen M, Voeller D, Marquez VE, Kaye FJ, Steeg PS, Giaccone G, Zajac-Kaye M.
Enhanced growth inhibition by combined DNA methylation/HDAC inhibitors in lung tumor cells with silenced CDKN2A.
Int. J. Oncol. 37: 963-71, 2010.
38)  Lockman PR, Mittapalli RK, Taskar KS, Rudraraju V, Gril B, Bohn KA, Adkins CE, Roberts A, Thorsheim HR, Gaasch JA, Huang S, Palmieri D, Steeg PS, Smith QR.
Heterogeneous blood-tumor barrier permeability determines drug efficacy in experimental brain metastases of breast cancer.
Clin. Cancer Res. 16: 5664-78, 2010.
39)  Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, Zajac-Kaye M, Chen M, Steinberg SM, Muir CA, Yancey MA, Horneffer YR, Juwara L, Melillo G, Ivy SP, Merino M, Neckers L, Steeg PS, Conley BA, Giaccone G, Doroshow JH, Murgo AJ.
Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies.
Eur. J. Cancer. 46: 340-7, 2010.
40)  Gril B, Evans L, Palmieri D, Steeg PS.
Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies.
Eur. J. Cancer. 46: 1204-10, 2010.
41)  Lee JH, Marshall J, Steeg PS, Horak CE.
Altered gene and protein expression by Nm23-H1 in metastasis suppression.
Mol. Cell. Biochem. 329: 141-8, 2009.
42)  Palmieri D, Fitzgerald D, Shreeve S, Hua E, Bronder J, Weil R, Davis S, Stark A, Merino M, Kurek R, Medhorn H, Davis G, Steinberg S, Meltzer P, Aldape K, Steeg P.
Analyses of resected human brain metastases of breast cancer reveal the association between up-regulation of hexokinase 2 and poor prognosis.
Mol Cancer Res. 7: 1438-45, 2009.
43)  Lu J, Steeg PS, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D.
Breast cancer metastasis: challenges and opportunities.
Cancer Res. 69: 4951-3, 2009.
44)  Marshall J, Lee JH, Steeg PS.
Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression.
Mol. Cell. Biochem. 329: 115-20, 2009.
45)  Steeg P, Anderson R, Bar-Eli M, Chambers A, Eccles S, Hunter K, Itoh K, Kang Y, Matrisian L, Sleeman J, Theodorescu D, Thompson E, Welch D.
Preclinical drug development must consider the impact on metastasis.
Clin Cancer Res. 15: 4529-30, 2009.
46)  Li SH, Hawthorne VS, Neal CL, Sanghera S, Xu J, Yang J, Guo H, Steeg PS, Yu D.
Upregulation of neutrophil gelatinase-associated lipocalin by ErbB2 through nuclear factor-kappaB activation.
Cancer Res. 69: 9163-8, 2009.
47)  Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR, Smith QR.
Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer.
Pharm. Res. 26: 2486-94, 2009.
48)  Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.
Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.
Mol. Cancer Ther. 8: 1589-95, 2009.
49)  Palmieri D, Lockman P, Thomas F, Hua E, Herring J, Hargrave E, Johnson M, Flores N, Qian Y, Vega-Valle E, Taskar K, Gaasch J, Liewehr D, Davis S, Riley J, Walkerm R, Bronder J, Feigenbaum L, Steinberg S, Camphausen K, Meltzer P, Richon V, Smith Q, Steeg P.
Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks.
Clin Cancer Res. 15: 6148-57, 2009.
50)  Lee JH, Horak CE, Khanna C, Meng Z, Yu LR, Veenstra TD, Steeg PS.
Alterations in Gemin5 expression contribute to alternative mRNA splicing patterns and tumor cell motility.
Cancer Res. 68: 639-44, 2008.
51)  Steeg PS, Horak CE, Miller KD.
Clinical-translational approaches to the Nm23-H1 metastasis suppressor.
Clin. Cancer Res. 14: 5006-12, 2008.
52)  Gril B, Palmieri D, Bronder JL, Herring JM, Vega-Valle E, Feigenbaum L, Liewehr DJ, Steinberg SM, Merino MJ, Rubin SD, Steeg PS.
Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain.
J. Natl. Cancer Inst. 100: 1092-103, 2008.
53)  Steeg PS.
Heterogeneity of drug target expression among metastatic lesions: lessons from a breast cancer autopsy program.
Clin. Cancer Res. 14: 3643-5, 2008.
54)  Kil WJ, Cerna D, Burgan WE, Beam K, Carter D, Steeg PS, Tofilon PJ, Camphausen K.
In vitro and in vivo radiosensitization induced by the DNA methylating agent temozolomide.
Clin. Cancer Res. 14: 931-8, 2008.
55)  Steeg PS, Theodorescu D.
Metastasis: a therapeutic target for cancer.
Nat. Clin. Pract. Oncol. 5: 206-19, 2008.
56)  Huang FJ, Steeg PS, Price JE, Chiu WT, Chou PC, Xie K, Sawaya R, Huang S.
Molecular basis for the critical role of suppressor of cytokine signaling-1 in melanoma brain metastasis.
Cancer Res. 68: 9634-42, 2008.
57)  McDermott WG, Boissan M, Lacombe ML, Steeg PS, Horak CE.
Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth.
Clin. Exp. Metastasis. 25: 131-8, 2008.
58)  Nishizuka S, Ramalingam S, Spurrier B, Washburn FL, Krishna R, Honkanen P, Young L, Tsutomu S, Steeg PS, Austin J.
Quantitative protein network monitoring in response to DNA damage.
J. Proteome Res. 7: 803-8, 2008.
59)  Fitzgerald DP, Palmieri D, Hua E, Hargrave E, Herring JM, Qian Y, Vega-Valle E, Weil RJ, Stark AM, Vortmeyer AO, Steeg PS.
Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization.
Clin. Exp. Metastasis. 25: 799-810, 2008.
60)  Horak CE, Lee JH, Marshall JC, Shreeve SM, Steeg PS.
The role of metastasis suppressor genes in metastatic dormancy.
APMIS. 116: 586-601, 2008.
61)  Varticovski L, Hollingshead MG, Robles AI, Wu X, Cherry J, Munroe DJ, Lukes L, Anver MR, Carter JP, Borgel SD, Stotler H, Bonomi CA, Nunez NP, Hursting SD, Qiao W, Deng CX, Green JE, Hunter KW, Merlino G, Steeg PS, Wakefield LM, Barrett JC.
Accelerated preclinical testing using transplanted tumors from genetically engineered mouse breast cancer models.
Clin. Cancer Res. 13: 2168-77, 2007.
62)  Palmieri D, Smith QR, Lockman PR, Bronder J, Gril B, Chambers AF, Weil RJ, Steeg PS.
Brain metastases of breast cancer.
Breast Dis. 26: 139-47, 2007.
63)  Steeg PS.
Cancer: micromanagement of metastasis.
Nature. 449: 671-3, 2007.
64)  Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, Aldape K, Steeg PS.
Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain.
Cancer Res. 67: 4190-8, 2007.
65)  Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, Borojerdi J, Warfel NA, Gardner ER, Danish M, Hollander MC, Kawabata S, Tsokos M, Figg WD, Steeg PS, Dennis PA.
Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Clin. Cancer Res. 13: 5183-94, 2007.
66)  Horak CE, Mendoza A, Vega-Valle E, Albaugh M, Graff-Cherry C, McDermott WG, Hua E, Merino MJ, Steinberg SM, Khanna C, Steeg PS.
Nm23-H1 suppresses metastasis by inhibiting expression of the lysophosphatidic acid receptor EDG2.
Cancer Res. 67: 11751-9, 2007.
67)  Horak CE, Lee JH, Elkahloun AG, Boissan M, Dumont S, Maga TK, Arnaud-Dabernat S, Palmieri D, Stetler-Stevenson WG, Lacombe ML, Meltzer PS, Steeg PS.
Nm23-H1 suppresses tumor cell motility by down-regulating the lysophosphatidic acid receptor EDG2.
Cancer Res. 67: 7238-46, 2007.
68)  Ramalingam S, Honkanen P, Young L, Shimura T, Austin J, Steeg PS, Nishizuka S.
Quantitative assessment of the p53-Mdm2 feedback loop using protein lysate microarrays.
Cancer Res. 67: 6247-52, 2007.
69)  Palmieri D, Chambers AF, Felding-Habermann B, Huang S, Steeg PS.
The biology of metastasis to a sanctuary site.
Clin. Cancer Res. 13: 1656-62, 2007.
70)  Athauda G, Giubellino A, Coleman JA, Horak C, Steeg PS, Lee MJ, Trepel J, Wimberly J, Sun J, Coxon A, Burgess TL, Bottaro DP.
c-Met Ectodomain Shedding Rate Correlates with Malignant Potential.
Clin. Cancer Res. 12: 4154-62, 2006.
71)  Danforth DN, Abati A, Filie A, Prindiville SA, Palmieri D, Simon R, Ried T, Steeg PS.
Combined breast ductal lavage and ductal endoscopy for the evaluation of the high-risk breast: a feasibility study.
J. Surg. Oncol. 94: 555-64, 2006.
72)  Heyn C, Ronald JA, Ramadan SS, Snir JA, Barry AM, MacKenzie LT, Mikulis DJ, Palmieri D, Bronder JL, Steeg PS, Yoneda T, MacDonald IC, Chambers AF, Rutt BK, Foster PJ.
In vivo MRI of cancer cell fate at the single-cell level in a mouse model of breast cancer metastasis to the brain.
Magn. Reson. Med. 56: 1001-10, 2006.
73)  Palmieri D, Bouadis A, Ronchetti R, Merino MJ, Steeg PS.
Rab11a Differentially Modulates Epidermal Growth Factor-induced Proliferation and Motility in Immortal Breast Cells.
Breast Cancer Res. Treat. 100: 127-37, 2006.
74)  Cysyk RL, Parker RJ, Barchi JJ, Steeg PS, Hartman NR, Strong JM.
Reaction of geldanamycin and C17-substituted analogues with glutathione: product identifications and pharmacological implications.
Chem. Res. Toxicol. 19: 376-81, 2006.
75)  Palmieri D, Horak CE, Lee J, Halverson DO, Steeg PS.
Translational approaches using metastasis suppressor genes.
J. Bioenerg. Biomembr. 38: 151-61, 2006.
76)  Steeg PS.
Tumor metastasis: mechanistic insights and clinical challenges.
Nat. Med. 12: 895-904, 2006.
77)  Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS.
Breast cancer metastasis to the central nervous system.
Am. J. Pathol. 167: 913-20, 2005.
78)  Steeg PS.
Cancer biology: emissaries set up new sites.
Nature. 438: 750-1, 2005.
79)  Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, Steinberg SM, Merino MJ, Steeg PS.
Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer.
J Natl Cancer Inst. 97: 632-42, 2005.
80)  Horak CE, Steeg PS.
Metastasis gets site specific.
Cancer Cell. 8: 93-5, 2005.
81)  Steeg PS.
New insights into the tumor metastatic process revealed by gene expression profiling.
Am J Pathol. 166: 1291-4, 2005.
82)  Salerno M, Palmieri D, Bouadis A, Halverson D, Steeg PS.
Nm23-H1 metastasis suppressor expression level influences the binding properties, stability, and function of the kinase suppressor of Ras1 (KSR1) Erk scaffold in breast carcinoma cells.
Mol Cell Biol. 25: 1379-88, 2005.
83)  Steeg PS.
Lippman ME, Morrow M, Osborne CK, eds.
Control of Invasion and Metastasis. In: Diseases of the Breast, Third Edition.
New York: Lippencott & Wilkens; 2004. p. 459-472 [Book Chapter]
84)  Steeg PS.
Perspectives on classic article: metastasis suppressor genes.
J Natl Cancer Inst. 96: E4, 2004.
85)  Steeg PS.
The gift of absorption.
Cancer Biol Ther. 3: 415-8, 2004.
86)  Kieran MW, Folkman J, Heymach J.
Angiogenesis inhibitors and hypoxia.
Nat. Med. 9: 1104; author reply 1104-5, 2003.
87)  Steeg PS.
Angiogenesis inhibitors: motivators of metastasis?.
Nat Med. 9: 822-3, 2003.
88)  Ouatas T, Salerno M, Palmieri D, Steeg PS.
Basic and translational advances in cancer metastasis: Nm23.
J Bioenerg Biomembr. 35: 73-9, 2003.
89)  Ouatas T, Halverson D, Steeg PS.
Dexamethasone and medroxyprogesterone acetate elevate nm23-h1 metastasis suppressor gene expression in metastatic human breast carcinoma cells: new uses for old compounds.
Clin Cancer Res. 9: 3763-72, 2003.
90)  Steeg PS, Palmieri D, Ouatas T, Salerno M.
Histidine kinases and histidine phosphorylated proteins in mammalian cell biology, signal transduction and cancer.
Cancer Lett. 190: 1-12, 2003.
91)  Salerno M, Ouatas T, Palmieri D, Steeg PS.
Inhibition of signal transduction by the nm23 metastasis suppressor: possible mechanisms.
Clin Exp Metastasis. 20: 3-10, 2003.
92)  Steeg PS, Ouatas T, Halverson D, Palmieri D, Salerno M.
Metastasis suppressor genes: basic biology and potential clinical use.
Clin Breast Cancer. 4: 51-62, 2003.
93)  Steeg PS.
Metastasis suppressors alter the signal transduction of cancer cells.
Nat Rev Cancer. 3: 55-63, 2003.
94)  Wulfkuhle JD, Paweletz CP, Steeg PS, Petricoin EF, Liotta L.
Proteomic approaches to the diagnosis, treatment, and monitoring of cancer.
Adv Exp Med Biol. 532: 59-68, 2003.
95)  Ouatas T, Clare SE, Hartsough MT, De La Rosa A, Steeg PS.
MMTV-associated transcription factor binding sites increase nm23-H1 metastasis suppressor gene expression in human breast carcinoma cell lines.
Clin Exp Metastasis. 19: 35-42, 2002.
96)  Hartsough MT, Morrison DK, Salerno M, Palmieri D, Ouatas T, Mair M, Patrick J, Steeg PS.
Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of Ras via a histidine protein kinase pathway.
J Biol Chem. 277: 32389-99, 2002.
97)  Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF, Zhao Y, Steeg PS.
Proteomics of human breast ductal carcinoma in situ.
Cancer Res. 62: 6740-9, 2002.
98)  Steeg PS.
Collapsin response mediator protein-1: a lung cancer invasion suppressor gene with nerve.
J Natl Cancer Inst. 93: 1364-5, 2001.
99)  Zhou Q, Hopp T, Fuqua SA, Steeg PS.
Cyclin D1 in breast premalignancy and early breast cancer: implications for prevention and treatment.
Cancer Lett. 162: 3-17, 2001.
100)  Hartsough MT, Clare SE, Mair M, Elkahloun AG, Sgroi D, Osborne CK, Clark G, Steeg PS.
Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition.
Cancer Res. 61: 2320-7, 2001.
101)  Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF.
New approaches to proteomic analysis of breast cancer.
Proteomics. 1: 1205-15, 2001.
102)  Steeg PS.
Molecular biology of breast cancer metastasis. 'Has it spread?': disarming one of the most terrifying questions.
Breast Cancer Res. 2: 396-9, 2000.
103)  Welch DR, Steeg PS, Rinker-Schaeffer CW.
Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis.
Breast Cancer Res. 2: 408-16, 2000.
104)  Hartsough MT, Steeg PS.
Nm23/nucleoside diphosphate kinase in human cancers.
J Bioenerg Biomembr. 32: 301-8, 2000.
105)  Zhou Q, Fukushima P, DeGraff W, Mitchell JB, Stetler Stevenson M, Ashkenazi A, Steeg PS.
Radiation and the Apo2L/TRAIL apoptotic pathway preferentially inhibit the colonization of premalignant human breast cells overexpressing cyclin D1.
Cancer Res. 60: 2611-5, 2000.
Click Here to View Collapsed Bibliography.

This page was last updated on 8/6/2014.